“Pnemotex” is approved for use not only in children, but also in adults.

MOSCOW, September 29. /TASS/. The pneumococcal infection vaccine Pnemotex, developed by the Russian biopharmaceutical company Nanolek, has been officially registered in Russia. The company’s press service reported this to TASS on Thursday.

“Last week, the domestically produced 13-valent pneumococcal polysaccharide conjugate adsorbed vaccine was registered. The full production cycle will be carried out in Russia. The vaccine will be available free of charge to Russian citizens,” the statement said.

Pnemotex is approved for use not only in children, but also in adults. The availability of this vaccine will ensure supply stability and give the state confidence that Russian residents will be provided with the product, noted Maksim Stetsyuk, First Deputy CEO of Nanolek.

The company reminded that pneumococcal infection can cause severe complications, disability, and death in young children. According to the World Health Organization and the Russian Ministry of Health, pneumococcus more often than other infections leads to pneumonia and bacterial otitis in children under five, and infants most frequently die from diseases caused by this infection. In addition, pneumococcus is considered one of the causes of sinusitis and bacterial meningitis and can also lead to sepsis.

Pneumococcal vaccination has been part of Russia’s National Immunization Schedule since 2014, given to children at 2, 4.5, and 15 months of age. It is also included in the schedule of vaccinations for epidemic indications for children aged two to five and for adults in risk groups, Nanolek added.

Nanolek is a Russian biopharmaceutical company founded in 2011 by Vladimir Khristenko and Mikhail Nekrasov. It specializes in producing import-substituting and innovative medicinal products and is one of the leaders in pediatric vaccine manufacturing in Russia. In addition to vaccines, its portfolio includes treatments for HIV, oncology, and rare diseases.